ReviewCurrent opinion in allergy and clinical immunology2012
Safety of engineered allergen-specific immunotherapy vaccines.
Review in Current opinion in allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Bioengineering Interventions to Enhance the Capacity of the Gut Microbiota in Controlling Food Allergies.Life (Basel, Switzerland) · 2026Review
- Homology modeling and epitope prediction of Der f 33.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.EBioMedicine · 2016Article
- Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.The Journal of allergy and clinical immunology · 2015Article
- Food allergies: the basics.Gastroenterology · 2015Review
- Mold allergens in respiratory allergy: from structure to therapy.Allergy, asthma & immunology research · 2015Review
- Modified allergens and their potential to treat allergic disease.Current allergy and asthma reports · 2014Review
- Cow's milk allergy: from allergens to new forms of diagnosis, therapy and prevention.Methods (San Diego, Calif.) · 2014Article
- Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5.The Journal of allergy and clinical immunology · 2014Article
- New vaccines for Mammalian allergy using molecular approaches.Frontiers in immunology · 2014Review
- Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy.Current treatment options in allergy · 2014Review
- Cloning, expression, and analysis of a cDNA coding for the Dermatophagoides farinae group 21 (Der f 21) allergen.American journal of translational research · 2014Article
- Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2013Review
- An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy.Allergy · 2013Article
- Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.Current allergy and asthma reports · 2013Review
- New directions in immunotherapy.Current allergy and asthma reports · 2013Review
- Computational vaccinology and the ICoVax 2012 workshop.BMC bioinformatics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe purpose of the review is to summarize and comment on recent developments regarding the safety of engineered immunotherapy vaccines. RECENT
findingsIn the last 2 years, several studies were published in which allergy vaccines were developed on the basis of chemical modification of natural allergen extracts, the engineering of allergen molecules by recombinant DNA technology and synthetic peptide chemistry, allergen genes, new application routes and conjugation with immune modulatory molecules. Several studies exemplified the general applicability of hypoallergenic vaccines on the basis of recombinant fusion proteins consisting of nonallergenic allergen-derived peptides fused to allergen-unrelated carrier molecules. These vaccines are engineered to reduce both, immunoglobulin E (IgE) as well as allergen-specific T cell epitopes in the vaccines, and thus should provoke less IgE and T-cell-mediated side-effects. They are made to induce allergen-specific IgG antibodies against the IgE-binding sites of allergens with the T-cell help of the carrier molecule. SUMMARY: Several interesting examples of allergy vaccines with potentially increased safety profiles have been published. The concept of fusion proteins consisting of allergen-derived hypoallergenic peptides fused to allergen-unrelated proteins that seems to be broadly applicable for a variety of allergens appears to be of particular interest because it promises not only to reduce side-effects but also to increase efficacy and convenience of allergy vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.